More information on Myrtelle’s clinical trial in Canavan disease can be found on https://clinicaltrials.gov/ under the identifier NCT04833907 or by emailing PatientAdvocacy@MyrtelleGTX.com.

Myrtelle Inc. announced updated findings of the open-label phase 1/2 clinical trial of its recombinant adeno-associated virus vector-based investigational gene therapy for Canavan disease, a fatal ...

More information on Myrtelle’s clinical study in Canavan disease can be found on https://clinicaltrials.gov/ under the identifier NCT04833907 or by emailing PatientAdvocacy@MyrtelleGTX.com.

"This is a transformative moment for Myrtelle and the entire Canavan disease community," said Adrian Stecyk, Chief Executive Officer of Myrtelle. "Initiating commercial manufacturing represents ...

In April, Mark H. Tuszynski, a neuroscientist at the University of California, San Diego, initiated an eight-subject trial in which he infects cultured fibroblasts with a recombinant virus and then ...

Canavan disease is a rare, inherited leukodystrophy arising from mutations in the ASPA gene, which result in reduced activity of the enzyme aspartoacylase. This enzyme deficiency leads to the ...

More information on Myrtelle's clinical trial in Canavan disease can be found on https://clinicaltrials.gov/ under the identifier NCT04833907 or by emailing PatientAdvocacy@MyrtelleGTX.com.